Drugs / NNC6022-0001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06336005 | Mar 2024 → Feb 2025 | cardiovascular-kidney-metabolic syndrome | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC6022-0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06336005 ↗ |